Translating research into society: innovation, transference, and public engagement.

At MELIS-UPF, we focus on translating laboratory insights into practical medical and industrial applications. In 2025, our technology transfer initiatives made steady progress. For instance, MELIS researchers secured six competitive grants specifically for technology transfer actions, amounting to nearly €3 million, from prestigious funding programs including EIC Transition, ERC Proof of Concept, and CaixaImpulse.

We are happy to be part of a growing innovation ecosystem. To date, MELIS has fostered a dynamic portfolio of research-driven spin-offs, including Integra Therapeutics, NoctuRNA Therapeutics, KOA Biotech SL, Disrupt Therapeutics, MedBioInformatics SL, BIOM- Bioinspired Materials, and Quantitative Genomic Medicine Laboratories, SL (qGenomics). In 2025, MELIS professor Marc Güell co-founded Thesian Bio (https://www.thesianbio.com/), a spin-off company aimed at harnessing the immune system to treat cancer and autoimmune disorders.